Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Berking

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patientsM V Heppt, M Schlaak, T K Eigentler, et al.
Genes and Immunity|May 22, 2009
Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control studyN Schoof, F von Bonin, I R König, et al.
ESMO Open|August 26, 2021
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapyJ C Hassel, E Livingstone, J P Allam, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.
The British Journal of Dermatology|May 21, 2014
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safetyJ Malvehy, A Hauschild, C Curiel-Lewandrowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patientsM V Heppt, M Schlaak, T K Eigentler, et al.
Genes and Immunity|May 22, 2009
Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control studyN Schoof, F von Bonin, I R König, et al.
ESMO Open|August 26, 2021
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapyJ C Hassel, E Livingstone, J P Allam, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.
The British Journal of Dermatology|May 21, 2014
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safetyJ Malvehy, A Hauschild, C Curiel-Lewandrowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
Pageof 11